Industry News
Pharmaceutical Industry News
If at first you don’t succeed in…
If at first you don’t succeed in gene therapy, then try, try again, is the lesson Ultragenyx likely took home this week, pocketing its first FDA nod in the class a little over a year
Moderna, Merck Say mRNA Vaccine Prevents Melanoma From Returning
Moderna and Merck say the experimental vaccine prevented the return and spread of the cancer in high-risk melanoma patients.
Hundreds of thousands of patients…
Hundreds of thousands of patients with type 2 diabetes could eventually make the switch to a weekly insulin injection and reduce their annual injections by 85% after NICE, the U.K.’s drug cost watchdog, gave Lilly's
Just eight months after it…
Just eight months after it introduced its Wegovy pill, Novo Nordisk is testing the GLP-1 in smaller doses in the phase 3 OASIS 5 study.
HCP marketers have spent years…
HCP marketers have spent years perfecting whom to reach. The harder question, and the one that decides whether a message lands, is when.
For the first time, SK…
For the first time, SK Biopharmaceuticals has reached a settlement with a generics manufacturer that has applied for FDA approval of a copycat version of its epilepsy treatment Xcopri, local news outlets report. SK’s deal
The summer of the high-potency…
The summer of the high-potency active pharmaceutical ingredient expansion continues, as yet another manufacturing specialist makes inroads to boost capacity for sensitive, in-demand drug ingredients.
Jazz’s bispecific antibody…
Jazz’s bispecific antibody Ziihera has gained an FDA approval for first-line HER2-positive stomach cancer, unlocking another market as the company builds toward a $2 billion-plus peak sales target.
After receiving a checkered…
After receiving a checkered regulatory scorecard in 2024, Aurobindo’s sterile injectables and oncology unit is back in the FDA’s crosshairs.
When clients start directing more…
When clients start directing more and agencies start thinking less, it may feel like the relationship has run its course. But starting over isn’t the only way to get fresh thinking.
Genetix Biotherapeutics is teaming…
Genetix Biotherapeutics is teaming up with the NFL Alumni Association for a U.S. awareness and education drive centered on sickle cell disease.
In challenging IRA price…
In challenging IRA price negotiations, Teva Pharmaceuticals has gained a partial win as the U.S. Court of Appeals for Washington, D.C., sent a previous ruling back to a lower court for further review. The challenge
Fierce editors break down Big…
Fierce editors break down Big Pharma’s second-quarter results, from AI and new leadership to the oral GLP-1 race and potential new blockbusters.
Valeris’ newly appointed chief…
Valeris' newly appointed chief strategy officer, Lauren Cole, comes from Merck subsidiary Verona Pharma, where she headed up patient services.
Biokin Pharma’s iza-bren, a…
Biokin Pharma’s iza-bren, a first-in-class antibody-drug conjugate partnered with Bristol Myers Squibb, has posted another positive phase 3 readout.
After a year of impairments,…
After a year of impairments, revenue downgrades and the ousting of its chief executive officer, Australian plasma and vaccine specialist CSL has flashed signs of recovery, projecting mid-single-digit growth in fiscal year 2027 for its
Revance has appointed Ulta Beauty…
Revance has appointed Ulta Beauty and Procter & Gamble alum Janelle Wichmann as its new chief marketing officer for skincare as it looks to boost commercial penetration of its Botox rival, Daxxify.
Regeneron’s Pasatru has crossed…
Regeneron's Pasatru has crossed the finish line with FDA approval after more than ten years of development. The drug is only the second approved treatment for FOP, an ultra-rare genetic condition that causes patients' soft
CMI Media Group has stepped up its…
CMI Media Group has stepped up its play for the orphan drug marketing sector, unveiling a framework tailored to the promotion of complex, low-incidence therapies.
After investors blanched last…
After investors blanched last month at a slower-than-expected launch timeline for Celcuity’s novel breast cancer med Revtorpyk, the company used much of its latest earnings call to address concerns over—and reaffirm confidence in—the pace of